Colin John Meyer - 03 Jan 2022 Form 4 Insider Report for REATA PHARMACEUTICALS INC

Role
Chief Research Officer
Signature
/s/ Tracy Herson, attorney-in-fact
Issuer symbol
N/A
Transactions as of
03 Jan 2022
Net transactions value
$0
Form type
4
Filing time
05 Jan 2022, 15:08:33 UTC
Previous filing
16 Jun 2021
Next filing
04 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RETA Class A common stock Award $0 +35,000 +206% $0.000000 52,000 03 Jan 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RETA Employee Stock Option (right to buy) Award $0 +70,000 $0.000000 70,000 03 Jan 2022 Class A common stock 70,000 $27.32 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares represent Restricted Stock Units, which vest in sixteen equal quarterly installments beginning on April 3, 2022, subject to continued service through each vesting date.
F2 The options vest in sixteen equal quarterly installments beginning on April 3, 2022, subject to continued service through each vesting date.